Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Silence Therapeutics. The associated price target remains the same with $75.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Silence Therapeutics’ strong potential for growth. The company is advancing multiple promising programs, including divesiran for polycythemia vera (PV) and zerlasiran for lipoprotein(a) [Lp(a)], both of which have shown significant progress in clinical trials. The updated Phase 1 data for divesiran, presented at the European Hematology Association, demonstrated effective hematocrit control and improved patient outcomes, positioning it as a potential first-in-class treatment.
Moreover, Silence Therapeutics is strategically prioritizing its resources by pausing less critical projects to focus on high-impact initiatives like PV and extra-hepatic delivery. The company’s collaboration with AstraZeneca and a strong cash position, with sufficient funds to sustain operations into 2028, further reinforce its financial stability and growth prospects. These factors, combined with upcoming clinical and business development milestones, support the analyst’s confidence in the stock’s upside potential, leading to the reiterated Buy rating and a price target of $75.
Trucchio covers the Healthcare sector, focusing on stocks such as GH Research, Arrowhead Pharmaceuticals, and Oncolytics Biotech. According to TipRanks, Trucchio has an average return of 13.6% and a 47.23% success rate on recommended stocks.